Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,556.41
(
0.48%
)
US TECH 100
29,377.60
(
0.68%
)
Dow Jones
50,665.26
(
0.04%
)
Brent Oil
93.41
(
1.04%
)
Bitcoin
72,694.91
(
-2.92%
)
News Focus
News Focus
Post# of 257649
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123029
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rwdm post# 213939

Thursday, 04/05/2018 10:12:13 AM

Thursday, April 05, 2018 10:12:13 AM

Post# of 257649
ABBV settles Humira-patent litigation with Samsung on terms more favorable (to ABBV) than the prior settlement with AMGN:

https://finance.yahoo.com/news/abbvie-announces-global-resolution-humira-120500818.html

Samsung Bioepis can launch its Humira FoB in the US on 6/30/23—five months later than AMGN’s launch date of 1/31/18 (#msg-134976468). I.e. AMGN effectively gained five months of Humira-FoB exclusivity in the US market by being the first to settle with ABBV.

Note: The Humira patents in question pertain to formulation and methods of use, not CoM.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today